Fixed-Dose Combination (Polypill) for Cardiovascular Disease Prevention: A Meta-Analysis

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Public Health

Background:

• Cardiovascular diseases remain a leading cause of mortality worldwide.
• Fixed-dose combination pills (polypills) offer a potential strategy to improve medication adherence and manage multiple cardiovascular risk factors simultaneously.
• Assessing the net clinical benefit of polypills requires robust evidence from randomized controlled trials.

Purpose of the Study:

• To conduct a meta-analysis of randomized trials to evaluate the efficacy of polypills in reducing cardiovascular mortality and major adverse cardiac events.
• To assess the impact of polypills on adherence and safety profiles compared to conventional treatment regimens.

Main Methods:

• A comprehensive literature search was conducted across Medline, Scopus, Web of Science, and Cochrane Central databases up to May 2021.
• Included randomized trials compared polypills (antihypertensive, lipid-lowering, ± antiplatelet agents) against control groups in patients at cardiovascular risk.
• Outcomes, including mortality, major adverse cardiac events, adherence, and side effects, were analyzed using risk ratios and standardized mean differences with 95% confidence intervals.

Main Results:

• The meta-analysis included 16 trials with 26,567 participants. Polypills did not significantly reduce all-cause mortality (RR 0.90; 95% CI 0.79-1.01) or major adverse cardiac events (RR 0.84; 95% CI 0.68-1.04).
• Significant reductions in systolic and diastolic blood pressure, as well as total and LDL cholesterol, were observed in the polypill group.
• Higher adherence rates (RR 1.18; 95% CI 1.06-1.32) and comparable adverse side effect rates (RR 1.10; 95% CI 0.98-1.23) were noted for polypills.

Conclusions:

• While polypills effectively reduce cardiovascular risk factors like blood pressure and cholesterol, they did not demonstrate a statistically significant mortality benefit in this meta-analysis.
• Subgroup analyses suggested potential benefits in primary prevention and long-term follow-up studies.
• Further research is warranted to confirm the clinical utility of polypills and identify specific patient populations that may derive the greatest benefit.